These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 23229280)

  • 41. Transcriptome Pathway Analysis of Pathological and Physiological Aldosterone-Producing Human Tissues.
    Zhou J; Lam B; Neogi SG; Yeo GS; Azizan EA; Brown MJ
    Hypertension; 2016 Dec; 68(6):1424-1431. PubMed ID: 27777363
    [TBL] [Abstract][Full Text] [Related]  

  • 42. KCNJ5 mutations in familial and non-familial primary aldosteronism.
    Al-Salameh A
    Eur J Endocrinol; 2024 Jun; 190(6):L9-L10. PubMed ID: 38781451
    [No Abstract]   [Full Text] [Related]  

  • 43. Aldosterone-Producing Adenomas: Histopathology-Genotype Correlation and Identification of a Novel
    Tan GC; Negro G; Pinggera A; Tizen Laim NMS; Mohamed Rose I; Ceral J; Ryska A; Chin LK; Kamaruddin NA; Mohd Mokhtar N; A Jamal AR; Sukor N; Solar M; Striessnig J; Brown MJ; Azizan EA
    Hypertension; 2017 Jul; 70(1):129-136. PubMed ID: 28584016
    [TBL] [Abstract][Full Text] [Related]  

  • 44. KCNJ5 mutations in aldosterone producing adenoma and relationship with adrenal cortex remodeling.
    Boulkroun S; Golib Dzib JF; Samson-Couterie B; Rosa FL; Rickard AJ; Meatchi T; Amar L; Benecke A; Zennaro MC
    Mol Cell Endocrinol; 2013 May; 371(1-2):221-7. PubMed ID: 23376008
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Genetic, Cellular, and Molecular Heterogeneity in Adrenals With Aldosterone-Producing Adenoma.
    De Sousa K; Boulkroun S; Baron S; Nanba K; Wack M; Rainey WE; Rocha A; Giscos-Douriez I; Meatchi T; Amar L; Travers S; Fernandes-Rosa FL; Zennaro MC
    Hypertension; 2020 Apr; 75(4):1034-1044. PubMed ID: 32114847
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Somatic KCNJ5 mutation occurring early in adrenal development may cause a novel form of juvenile primary aldosteronism.
    Tamura A; Nishimoto K; Seki T; Matsuzawa Y; Saito J; Omura M; Gomez-Sanchez CE; Makita K; Matsui S; Moriya N; Inoue A; Nagata M; Sasano H; Nakamura Y; Yamazaki Y; Kabe Y; Mukai K; Kosaka T; Oya M; Suematsu S; Nishikawa T
    Mol Cell Endocrinol; 2017 Feb; 441():134-139. PubMed ID: 27514282
    [TBL] [Abstract][Full Text] [Related]  

  • 47. An update on novel mechanisms of primary aldosteronism.
    Zennaro MC; Boulkroun S; Fernandes-Rosa F
    J Endocrinol; 2015 Feb; 224(2):R63-77. PubMed ID: 25424518
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Aldosterone-Producing Adenoma With a Somatic KCNJ5 Mutation Revealing APC-Dependent Familial Adenomatous Polyposis.
    Vouillarmet J; Fernandes-Rosa F; Graeppi-Dulac J; Lantelme P; Decaussin-Petrucci M; Thivolet C; Peix JL; Boulkroun S; Clauser E; Zennaro MC
    J Clin Endocrinol Metab; 2016 Nov; 101(11):3874-3878. PubMed ID: 27648962
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Emerging association between KCNJ5 mutations and vascular failure in primary aldosteronism.
    Jojima K; Tanaka A; Node K
    Hypertens Res; 2023 Nov; 46(11):2547-2550. PubMed ID: 37670004
    [No Abstract]   [Full Text] [Related]  

  • 50. Familial forms and molecular profile of primary hyperaldosteronism.
    Araujo-Castro M; Martín Rojas-Marcos P; Parra Ramírez P
    Hipertens Riesgo Vasc; 2022; 39(4):167-173. PubMed ID: 35778363
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Functional histopathological markers of aldosterone producing adenoma and somatic KCNJ5 mutations.
    Fernandes-Rosa FL; Amar L; Tissier F; Bertherat J; Meatchi T; Zennaro MC; Boulkroun S
    Mol Cell Endocrinol; 2015 Jun; 408():220-6. PubMed ID: 25617716
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Genetics of primary hyperaldosteronism.
    Dutta RK; Söderkvist P; Gimm O
    Endocr Relat Cancer; 2016 Oct; 23(10):R437-54. PubMed ID: 27485459
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Microarray, qPCR, and KCNJ5 sequencing of aldosterone-producing adenomas reveal differences in genotype and phenotype between zona glomerulosa- and zona fasciculata-like tumors.
    Azizan EA; Lam BY; Newhouse SJ; Zhou J; Kuc RE; Clarke J; Happerfield L; Marker A; Hoffman GJ; Brown MJ
    J Clin Endocrinol Metab; 2012 May; 97(5):E819-29. PubMed ID: 22442279
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacology and pathophysiology of mutated KCNJ5 found in adrenal aldosterone-producing adenomas.
    Tauber P; Penton D; Stindl J; Humberg E; Tegtmeier I; Sterner C; Beuschlein F; Reincke M; Barhanin J; Bandulik S; Warth R
    Endocrinology; 2014 Apr; 155(4):1353-62. PubMed ID: 24506072
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Regulation of aldosterone biosynthesis by the Kir3.4 (KCNJ5) potassium channel.
    Velarde-Miranda C; Gomez-Sanchez EP; Gomez-Sanchez CE
    Clin Exp Pharmacol Physiol; 2013 Dec; 40(12):895-901. PubMed ID: 23829355
    [TBL] [Abstract][Full Text] [Related]  

  • 56. KCNJ5 gene somatic mutations affect cardiac remodelling but do not preclude cure of high blood pressure and regression of left ventricular hypertrophy in primary aldosteronism.
    Rossi GP; Cesari M; Letizia C; Seccia TM; Cicala MV; Zinnamosca L; Kuppusamy M; Mareso S; Sciomer S; Iacobone M; Mantero F; Pessina AC
    J Hypertens; 2014 Jul; 32(7):1514-21; discussion 1522. PubMed ID: 24759126
    [TBL] [Abstract][Full Text] [Related]  

  • 57. KCNJ5 mutations in the National Institutes of Health cohort of patients with primary hyperaldosteronism: an infrequent genetic cause of Conn's syndrome.
    Xekouki P; Hatch MM; Lin L; Rodrigo de A; Azevedo M; de la Luz Sierra M; Levy I; Saloustros E; Moraitis A; Horvath A; Kebebew E; Hoffman DA; Stratakis CA
    Endocr Relat Cancer; 2012 Jun; 19(3):255-60. PubMed ID: 22323562
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Characterization of a novel somatic KCNJ5 mutation delI157 in an aldosterone-producing adenoma.
    Murthy M; Azizan EA; Brown MJ; O'Shaughnessy KM
    J Hypertens; 2012 Sep; 30(9):1827-33. PubMed ID: 22743686
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pathogenesis of Primary Aldosteronism: Impact on Clinical Outcome.
    Santana LS; Guimaraes AG; Almeida MQ
    Front Endocrinol (Lausanne); 2022; 13():927669. PubMed ID: 35813615
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Targeted disruption of the
    Hardege I; Long L; Al Maskari R; Figg N; O'Shaughnessy KM
    Clin Sci (Lond); 2018 Jan; 132(1):145-156. PubMed ID: 29222092
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.